

# ASSESSING PSORIASIS PATIENT CHARACTERISTICS AFTER BEING TREATED WITH FIRST LINE ADVANCED THERAPY FOR 12 MONTHS

MamTing Thoo<sup>1</sup>, Elizabeth Baynton<sup>2</sup>, Denise Baldock<sup>2</sup>, Hannah Brown<sup>2</sup>  
<sup>1</sup>Ipsos, Kuala Lumpur, Malaysia <sup>2</sup>Ipsos, London, United Kingdom

## INTRODUCTION

Skin clearance rates form fundamental efficacy assessments of biologics/targeted oral (advanced) therapies in psoriasis (PsO). Developmental molecules continue to be evaluated based on reductions in Psoriasis Area Severity Index (PASI) scores.

## OBJECTIVE

The objective of this study was to highlight characteristics of patients that did not experience high skin clearance scores, despite receiving advanced therapy, to understand possible areas of unmet need.

## METHODS

The Ipsos PsO Therapy Monitor, an ongoing multi-centre online medical chart review study of patients with PsO was conducted between Sep-Dec 2022 among dermatologists from UK, France, Germany, Italy and Spain. 221 sampled dermatologists were screened for practice duration, patient volume and ability to prescribe advanced therapies. 253 charts of patients with PsO who received their first ever advanced therapy for a duration of 12 months were included in the analysis.

## RESULTS

The patients who achieved PASI 75 after 12 months of advanced therapy were more likely to be considered 'severe' at diagnosis and 'mild' at their most recent consultation. Of the patients who did not achieve PASI 75, a greater proportion were considered 'severe' at their most recent consultation and were also more likely to experience depression/ anxiety.

## CONCLUSIONS

Comparisons in this study cohort highlight that patients who achieved PASI 75 after 12 months of treatment were more likely to be deemed 'severe' at diagnosis and experience metabolic conditions – it may be that this patient cohort was deemed 'higher risk' and treated in a different manner to the cohort who had not achieved PASI 75. It is worth exploring if nuances in treatment occur depending on different patient characteristics, and if those patients with less severe disease could benefit from adjusted treatment paradigms. Further investigation using comparator cohort is warranted.



# Patients in our study who did not achieve PASI 75 within a year of their first advanced therapy were more likely to present with severe PsO and depression/ anxiety.




SCAN TO DOWNLOAD THE POSTER & ABSTRACT

CONTACT US: [TherapyMonitors@ipsos.com](mailto:TherapyMonitors@ipsos.com)

E-POSTER NUMBER: P2508  
EADV 2023, BERLIN, 11 - 14 OCTOBER


## RESULTS

Figure 1: % of reported PsO patients with recorded disease severity at diagnosis




Source: Ipsos PsO Therapy Monitor (HCPs providing de-identified patient record data on PsO patients seen in consultation & perceptions online). Data are © Ipsos 2023, all rights reserved.

Figure 2: % of reported PsO patients with recorded disease severity at their most recent consultation



Source: Ipsos PsO Therapy Monitor (HCPs providing de-identified patient record data on PsO patients seen in consultation & perceptions online). Data are © Ipsos 2023, all rights reserved.

Figure 3: % of reported PsO patients recorded as experiencing specific co-morbidities



Source: Ipsos PsO Therapy Monitor (HCPs providing de-identified patient record data on PsO patients seen in consultation & perceptions online). Data are © Ipsos 2023, all rights reserved.